PCG
PBYI icon

Private Capital Group’s Puma Biotechnology PBYI Stock Holding History

Private Capital Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-51
Closed -$3K – 2402
2019
Q2 		$3K Buy
+51
New +$1.17K ﹤0.01% 1828
2018
Q3 		– Sell
-51
Closed -$3K – 2267
2018
Q2 		$3K Sell
51
-6
-11% -$348 ﹤0.01% 1813
2018
Q1 		$4K Sell
57
-2,202
-97% -$165K ﹤0.01% 1676
2017
Q4 		$12K Buy
+2,259
New +$253K ﹤0.01% 1283

Other funds holding PBYI

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Private Capital Group's PBYI Position: Q3 2019 in Review

Private Capital Group sold out of Puma Biotechnology (PBYI) in Q3 2019, closing a stake of 51 shares — an estimated $3K sold.

Private Capital Group first reported a position in PBYI in Q4 2017 and held it in 4 quarters. The position peaked at $12K in Q4 2017. 144 funds tracked by Wall St. Rank hold PBYI as of Q3 2019.

  • Private Capital Group reported no remaining Puma Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Private Capital Group sold 51 Puma Biotechnology shares in Q3 2019, an estimated $3K.
  • Private Capital Group first reported a position in Puma Biotechnology in Q4 2017 and held it in 4 quarters.
  • Private Capital Group's Puma Biotechnology position peaked at $12K in Q4 2017.
  • 144 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2019.

Based on Private Capital Group's 13F filing for Q3 2019, filed 13 Nov 2019.